ConductScience.org, home

Paper3105134

Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation.

Goldstein G. Transplant Proc, 1987. Cited by 109 papers, by iCite.

Cite this record

ConductScience Library. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation. Papers, record 3105134. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3105134

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation.
PubMed
Journal
Transplant Proc
PubMed
Year
1987
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
109
iCite
Relative citation ratio, by iCite
3.02
iCite
Revised in PubMed
2021-12-03
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Goldstein GG

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
Graft RejectionMajor topic
T-LymphocytesMajor topic
Animals
Antibodies, Anti-Idiotypic
Antigens, Differentiation, T-Lymphocyte
Antigens, Surface
Heart Transplantation
Humans
Hybridomas
Immunoglobulin Idiotypes
Immunosuppression Therapy
Kidney Transplantation
Liver Transplantation
Muromonab-CD3

Source PubMed

Download CSV of topics

Cited by21

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 109 citations.

PMIDTitleJournalYearIn PapersSource
40861455An explorable model of an adverse outcome pathway of cytokine release syndrome related to the administration of immunomodulatory biotherapeutics and cellular therapies.Front Immunol2025https://conductscience.org/library/papers/40861455PubMed
39312187Integrated Imaging Probe and Bispecific Antibody Development Enables In Vivo Targeting of Glypican-3-Expressing Hepatocellular Carcinoma.Mol Cancer Ther2024https://conductscience.org/library/papers/39312187PubMed
34445651The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies.Int J Mol Sci2021https://conductscience.org/library/papers/34445651PubMed
31836861Therapies for rare diseases: therapeutic modalities, progress and challenges ahead.Nat Rev Drug Discov2020https://conductscience.org/library/papers/31836861PubMed
28733914Molecular and functional analysis of monoclonal antibodies in support of biologics development.Protein Cell2018https://conductscience.org/library/papers/28733914PubMed
26441475Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studies.J Toxicol Pathol2015https://conductscience.org/library/papers/26441475PubMed
25484230Optimization of the crystallizability of a single-chain antibody fragment.Acta Crystallogr F Struct Biol Commun2014https://conductscience.org/library/papers/25484230PubMed
23751612Characterization of a surrogate murine antibody to model anti-human CD3 therapies.MAbs2013https://conductscience.org/library/papers/23751612PubMed
22939368The road to purified hematopoietic stem cell transplants is paved with antibodies.Curr Opin Immunol2012https://conductscience.org/library/papers/22939368PubMed
12529161Therapy for acute rejection in pediatric organ transplant recipients.Paediatr Drugs2003https://conductscience.org/library/papers/12529161PubMed
9246765Morphology of rat kidney and thymus after native and antibody-coupled cyclosporin A application (reduced toxicity of targeted drug).Folia Microbiol (Praha)1997https://conductscience.org/library/papers/9246765PubMed
8690455Sensitization of T-cell receptor-alpha beta+ T cells recovered from long-term T-cell receptor downmodulation.Immunology1996https://conductscience.org/library/papers/8690455PubMed
8439495Characterisation of a humanised bispecific monoclonal antibody for cancer therapy.Br J Cancer1993https://conductscience.org/library/papers/8439495PubMed
8251324New immunosuppressive agents for pediatric transplantation.Pediatr Nephrol1993https://conductscience.org/library/papers/8251324PubMed
8157269Inhibition of allograft rejection by anti-T-cell receptor-alpha beta monoclonal antibodies preserving resistance to bacterial infection.Immunology1994https://conductscience.org/library/papers/8157269PubMed
7680292Local immunosuppressive therapy with monoclonal anti-T cell antibody on renal allograft survival in the rat.Clin Exp Immunol1993https://conductscience.org/library/papers/7680292PubMed
2503348Muromonab CD3. A review of its pharmacology and therapeutic potential.Drugs1989https://conductscience.org/library/papers/2503348PubMed
1833167OKT3 prophylaxis in liver transplantation.Dig Dis Sci1991https://conductscience.org/library/papers/1833167PubMed
1753685Perspectives in transplantation immunology 1991.Klin Wochenschr1991https://conductscience.org/library/papers/1753685PubMed
1431256Factors associated with invasive lung aspergillosis and the significance of positive Aspergillus culture after liver transplantation.J Infect Dis1992https://conductscience.org/library/papers/1431256PubMed

See all 21 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/3105134

GET https://conductscience.org/api/papers/v1/3105134/cited_by?page=2